NNRTIs and protease inhibitors both good for first ART, channelling affects choices

postato in: Senza categoria | 0

reverse transcriptase inhibitors (NNRTIs) and boosted protease
inhibitors work equally well for people starting HIV treatment for the first
time, with similar viral suppression, CD4 cell gains, and disease
progression, according to a large meta-analysis presented
at IDWeek 2014 earlier this month in Philadelphia. A related study
shed light on factors affecting choice of
initial antiretroviral regimen.

Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV

postato in: Senza categoria | 0

A single-tablet
regimen containing the hepatitis C virus (HCV) nucleotide polymerase
inhibitor sofosbuvir and
the NS5A inhibitor ledipasvir – the combination in Gilead Science’s
recently approved Harvoni pill – was well-tolerated and cured 97% of
patients with HCV genotype 1 in the Phase 3 ION trials, researchers
reported at the IDWeek 2014 meeting earlier this month in
advent of direct-acting antiviral agents has revolutionized treatment for
chronic hepatitis C, especially with the long-awaited

HIV treatment roll-out has had only a modest impact on mortality in Lusaka, Zambia

postato in: Senza categoria | 0

The scale-up of
antiretroviral therapy (ART) programmes in Lusaka, Zambia, has been
accompanied by only modest reductions in the city’s mortality rates,
investigators report in the Bulletin of
the World Health Organization. A series of cross-sectional household
surveys conducted between 2004 and 2011 showed no significant reduction in the
mortality rate. The authors admit this finding

1 30 31 32 33 34